Abnormal hepatic energy homeostasis in type 2 diabetes
暂无分享,去创建一个
Ewald Moser | Peter Nowotny | Michael Roden | Marek Chmelik | E. Moser | M. Roden | J. Szendroedi | A. Brehm | P. Nowotny | M. Krššák | Martin Krssak | Julia Szendroedi | Albrecht Ingo Schmid | Attila Brehm | A. I. Schmid | M. Chmelík
[1] R. Pandey,et al. Investigation of hepatic gluconeogenesis pathway in non-diabetic Asian Indians with non-alcoholic fatty liver disease using in vivo ((31)P) phosphorus magnetic resonance spectroscopy. , 2009, Atherosclerosis.
[2] M. Roden,et al. Ectopic lipids and organ function , 2009, Current opinion in lipidology.
[3] V. Darley-Usmar,et al. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo , 2008, The Biochemical journal.
[4] S. Schinner. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[5] E. Moser,et al. Three‐dimensional high‐resolution magnetic resonance spectroscopic imaging for absolute quantification of 31P metabolites in human liver , 2008, Magnetic resonance in medicine.
[6] F. Schick,et al. (1)H MR spectroscopy of skeletal muscle, liver and bone marrow. , 2008, European journal of radiology.
[7] A. Lonardo,et al. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. , 2008, Clinical science.
[8] E Moser,et al. Quantitative ATP synthesis in human liver measured by localized 31P spectroscopy using the magnetization transfer experiment , 2008, NMR in biomedicine.
[9] S. Mantena,et al. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. , 2008, Free radical biology & medicine.
[10] Olga Ilkayeva,et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. , 2008, Cell metabolism.
[11] M. Wolzt,et al. Muscle Mitochondrial ATP Synthesis and Glucose Transport/Phosphorylation in Type 2 Diabetes , 2007, PLoS medicine.
[12] Zdeněk Tošner,et al. Application of two-dimensional CSI for absolute quantification of phosphorus metabolites in the human liver , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[13] D. Graveron-Demilly,et al. Java-based graphical user interface for the MRUI quantitation package , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.
[14] S. Takase,et al. Mutation of mitochondrial DNA in livers from patients with alcoholic hepatitis and nonalcoholic steatohepatitis. , 2007, Alcoholism, clinical and experimental research.
[15] J. Hardies,et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.
[16] Michael Roden,et al. Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.
[17] G. Farrell,et al. Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.
[18] Peter Nowotny,et al. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. , 2006, Diabetes.
[19] K. Petersen,et al. Decreased Insulin-Stimulated ATP Synthesis and Phosphate Transport in Muscle of Insulin-Resistant Offspring of Type 2 Diabetic Parents , 2005, PLoS medicine.
[20] Jeanne M Clark,et al. Hepatic 31P magnetic resonance spectroscopy: a hepatologist's user guide , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[21] F. Schick,et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[22] P. Angulo,et al. Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.
[23] Jonathan C. Cohen,et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.
[24] C. Cobelli,et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. , 2004, Diabetes.
[25] D. Pessayre,et al. Mitochondrial injury in steatohepatitis , 2004, European journal of gastroenterology & hepatology.
[26] J. Horton,et al. Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.
[27] E. Björnsson,et al. High prevalence of metabolic complications in patients with non‐alcoholic fatty liver disease , 2004, Scandinavian journal of gastroenterology.
[28] J. Arenas,et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis , 2003, Hepatology.
[29] V. P. Chacko,et al. Hepatic ATP Reserve and Efficiency of Replenishing: Comparison Between Obese and Nonobese Normal Individuals , 2003, American Journal of Gastroenterology.
[30] M. Roden,et al. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. , 2002, Diabetes.
[31] C. Bogardus,et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. , 2002, Diabetes.
[32] G. Pacini,et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association , 2002, Hepatology.
[33] J. Clore,et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.
[34] M. Oudkerk,et al. Decreased energy and phosphorylation status in the liver of lung cancer patients with weight loss. , 2000, Journal of hepatology.
[35] H. Cortez‐Pinto,et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. , 1999, JAMA.
[36] J. Parks,et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. , 1999, Journal of hepatology.
[37] F. Schick,et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.
[38] M. Oudkerk,et al. Understanding the discrepancies between 31P MR spectroscopy assessed liver metabolite concentrations from different institutions. , 1998, Magnetic resonance imaging.
[39] Vanhamme,et al. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge , 1997, Journal of magnetic resonance.
[40] D. Aust,et al. Defects of the respiratory chain in the normal human liver and in cirrhosis during aging , 1997, Hepatology.
[41] R. Holman,et al. UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. , 1997, The Journal of clinical endocrinology and metabolism.
[42] Jimmy D Bell,et al. Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models. , 1996, Gut.
[43] T. Brown,et al. Molar Quantitation of Hepatic Metabolites In Vivo in Proton‐decoupled, Nuclear Overhauser Effect Enhanced 31P NMR Spectra Localized by Three‐dimensional Chemical Shift Imaging , 1996, NMR in biomedicine.
[44] C. Tiribelli,et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis , 1995, Journal of magnetic resonance imaging : JMRI.
[45] D. Menon,et al. Effect of functional grade and etiology on in vivo hepatic phosphorus‐31 magnetic resonance spectroscopy in cirrhosis: Biochemical basis of spectral appearances , 1995, Hepatology.
[46] C. Muhle,et al. In Vivo P‐31-MR‐Spectroscopy of Focal Hepatic Lesions: Effectiveness of Tumor Detection in Clinical Practice and Experimental Studies of Surface Coil Characteristics and Localization Technique , 1995, Investigative radiology.
[47] R. Buchli,et al. Assessment of absolute metabolite concentrations in human tissue by 31P MRS in vivo. Part II: Muscle, liver, kidney , 1994, Magnetic resonance in medicine.
[48] 山根 豊. Phosphorus-31 nuclear magnetic resonance in vivo spectroscopy of human liver during hepatitis A virus infection , 1994 .
[49] W G Bradley,et al. Quantitative P‐31 MR spectroscopy of the liver in alcoholic cirrhosis , 1992, Journal of magnetic resonance imaging : JMRI.
[50] B. Lauterburg,et al. Assessment of mitochondrial function in vivo with a breath test utilizing α—ketoisocaproic acid , 1989, Hepatology.
[51] M W Weiner,et al. Alcoholic liver disease: quantitative image-guided P-31 MR spectroscopy. , 1989, Radiology.
[52] B. Lauterburg,et al. Assessment of mitochondrial function in vivo with a breath test utilizing alpha-ketoisocaproic acid. , 1989, Hepatology.
[53] J. S. Cohen,et al. Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. , 1987, The Journal of biological chemistry.
[54] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.